Top

Published in:

Open Access 01-08-2020 | Breast Cancer | Brief Report

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Authors: Emma Sandén, Somayeh Khazaei, Helga Tryggvadottir, Signe Borgquist, Karolin Isaksson, Karin Jirström, Helena Jernström

Published in: Virchows Archiv | Issue 2/2020

Abstract

Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.

Escriva-de-Romani S, Arumi M, Bellet M, Saura C (2018) HER2-positive breast cancer: current and new therapeutic strategies. Breast 39:80–88. https://doi.org/10.1016/j.breast.2018.03.006 CrossRefPubMed

Regionala cancercentrum (2018) Swedish guidelines concerning breast pathology (Kvalitetsdokument för patologi). Available from: http://www.svfp.se/foreningar/uploads/L15178/kvast/brostpatologi/KVASTbrostcancer2018.pdf. Accessed 2019-11-01

Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R (2005) Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 29(11):1505–1511. https://doi.org/10.1097/01.pas.0000172294.67409.4f CrossRefPubMed

Varga Z, Tubbs RR, Moch H (2014) Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification. PLoS One 9(8):e105961. https://doi.org/10.1371/journal.pone.0105961 CrossRefPubMedPubMedCentral

Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, Grogan TM (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66(6):313–324. https://doi.org/10.1111/pin.12407 CrossRefPubMed

Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H (2017) Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: implications for prognosis in different treatment groups. Oncotarget 8(6):9093–9107. https://doi.org/10.18632/oncotarget.14082 CrossRefPubMed

Fernö M, Haglund M, Bendahl PO, Olsson H, Rydén L (2008) Analys av HER2 i bröstcancer kvalitetssäkrad. Läkartidningen 105(32):32–33

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329. https://doi.org/10.1093/annonc/mdp322 CrossRefPubMedPubMedCentral

Hedner C, Borg D, Nodin B, Karnevi E, Jirström K, Eberhard J (2018) Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. J Clin Pathol 71(5):451–462. https://doi.org/10.1136/jclinpath-2017-204774 CrossRefPubMed

10.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C (2016) Tissue microarray is a reliable tool for the evaluation of HER2 amplification in breast cancer. Anticancer Res 36(9):4661–4666. https://doi.org/10.21873/anticanres.11017 CrossRefPubMed

11.

Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ (2012) Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res 14(3):R93. https://doi.org/10.1186/bcr3208 CrossRefPubMedPubMedCentral

12.

Ekholm M, Grabau D, Bendahl PO, Bergh J, Elmberger G, Olsson H, Russo L, Viale G, Ferno M (2015) Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. Acta Oncol 54(7):1040–1048. https://doi.org/10.3109/0284186X.2015.1037012 CrossRefPubMed

13.

Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24(19):3032–3038. https://doi.org/10.1200/JCO.2005.03.4744 CrossRefPubMed

14.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C (2017) Concordance of HER2 immunohistochemistry and fluorescence in situ hybridization using tissue microarray in breast cancer. Anticancer Res 37(6):3323–3329. https://doi.org/10.21873/anticanres.11701 CrossRefPubMed

15.

Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA (2016) Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification. Breast Cancer Res 18(1):68. https://doi.org/10.1186/s13058-016-0725-1 CrossRefPubMedPubMedCentral

16.

Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW (2012) Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer 118(4):914–923. https://doi.org/10.1002/cncr.26406 CrossRefPubMed

Title: Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
Authors: Emma Sandén
Somayeh Khazaei
Helga Tryggvadottir
Signe Borgquist
Karolin Isaksson
Karin Jirström
Helena Jernström
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Published in: Virchows Archiv / Issue 2/2020
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-020-02768-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders

Prominent entrapment of respiratory epithelium in primary and metastatic intrapulmonary non-epithelial neoplasms: a frequent morphological pattern closely mimicking adenofibroma and other biphasic pulmonary lesions

Relevance of routine pathology review in cervical carcinoma

The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature

The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer

Correction to: PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders